About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NKTR · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 21, 2026A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Sev…
NCT07690371 · Moderate-to-Severe Atopic Dermatitis
Rezpegaldesleukin, Placebo
NKTR
Nektar Therapeutics
Phase 3Recruiting510May 2028Registry ↗
Oct 16, 2026NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Larg…
NCT05664217 · Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-c…
NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg
NKTR
Nektar Therapeutics
Phase 2/3Terminated15May 22, 2024Registry ↗
Sep 18, 2026A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe A…
NCT06340360 · Alopecia Areata
Rezpegaldesleukin, Placebo
NKTR
Nektar Therapeutics
Phase 2Completed94Nov 26, 2025Registry ↗
Sep 8, 2026A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Sev…
NCT07711418 · Moderate-to-Severe Atopic Dermatitis
Rezpegaldesleukin, Placebo
NKTR
Nektar Therapeutics
Phase 3Recruiting510Jun 2028Registry ↗
Aug 21, 2026A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Mod…
NCT06136741 · Moderate to Severe Atopic Dermatitis
Rezpegaldesleukin, Placebo
NKTR
Nektar Therapeutics
Phase 2Active, not recruiting396May 6, 2025Registry ↗
Jun 8, 2025Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
NCT04616196 · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
NKTR-255, Cetuximab
NKTR
Nektar Therapeutics
Phase 1/2Completed25Mar 30, 2023Registry ↗
Apr 23, 2024A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
NCT04433585 · Systemic Lupus Erythematosus
LY3471851, Placebo
NKTR
Nektar Therapeutics
Phase 2Completed291Jan 10, 2023Registry ↗
Mar 12, 2024A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patient…
NCT04646044 · Covid-19, Coronavirus Disease 2019
Bempegaldesleukin, Standard of Care
NKTR
Nektar Therapeutics
Phase 1Completed30May 11, 2021Registry ↗
Feb 20, 2024A Study of LY3471851 in Participants With Psoriasis
NCT04119557 · Psoriasis
Placebo, LY3471851
NKTR
Nektar Therapeutics
Phase 1Completed30Jul 21, 2021Registry ↗
Feb 20, 2024A Study of LY3471851 in Participants With Eczema
NCT04081350 · Dermatitis, Atopic
LY3471851, Placebo
NKTR
Nektar Therapeutics
Phase 1Completed48Jun 24, 2022Registry ↗
Nov 18, 2023A Phase I Study of LY3471851 in Healthy Participants
NCT05565729 · Healthy
LY3471851, Placebo
NKTR
Nektar Therapeutics
Phase 1Completed41Feb 23, 2023Registry ↗
Nov 18, 2023A Single-Dose Study of LY3471851 in Healthy Participants
NCT04998487 · Healthy
LY3471851
NKTR
Nektar Therapeutics
Phase 1Completed71Jul 6, 2022Registry ↗
Nov 18, 2023A Study of NKTR-358 (LY3471851) in Healthy Participants
NCT04380324 · Healthy
LY3471851, Placebo
NKTR
Nektar Therapeutics
Phase 1Completed100Jan 20, 2019Registry ↗
Nov 18, 2023A Study of LY3471851 in Healthy Participants
NCT04133116 · Healthy
LY3471851, Placebo
NKTR
Nektar Therapeutics
Phase 1Completed36Mar 6, 2020Registry ↗
Nov 18, 2023A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
NCT03556007 · Systemic Lupus Erythematosus
LY3471851, Placebo
NKTR
Nektar Therapeutics
Phase 1Completed48Aug 29, 2019Registry ↗
Sep 5, 2023A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (U…
NCT04677179 · Colitis, Ulcerative
LY3471851, Placebo
NKTR
Nektar Therapeutics
Phase 2Terminated81Aug 9, 2022Registry ↗
Jun 15, 2023NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NCT04136756 · Multiple Myeloma, Non-Hodgkin Lymphoma
NKTR-255, NKTR-255 Q21
NKTR
Nektar Therapeutics
Phase 1Completed30Apr 24, 2023Registry ↗
Apr 21, 2023Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolum…
NCT04410445 · Melanoma, Melanoma Stage III
Bempegaldesleukin, Nivolumab
NKTR
Nektar Therapeutics
Phase 3Terminated765Sep 22, 2022Registry ↗
Apr 14, 2023A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients W…
NCT02915744 · Metastasis, Breast Cancer
NKTR-102, Eribulin
NKTR
Nektar Therapeutics
Phase 3Completed178Jul 2020Registry ↗
Apr 11, 2023A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Inv…
NCT03729245 · Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
bempegaldesleukin, sunitinib
NKTR
Nektar Therapeutics
Phase 3Terminated623Jan 7, 2022Registry ↗
Mar 28, 2023A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients…
NCT03785925 · Urinary Bladder Neoplasm, Neoplasm Metastasis
Bempegaldesleukin, Nivolumab
NKTR
Nektar Therapeutics
Phase 2Completed192Feb 9, 2022Registry ↗
Mar 13, 2023A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other An…
NCT02983045 · Melanoma, Renal Cell Carcinoma
Dose Escalation Doublet: Combination of NKTR-214 + nivoluma…
NKTR
Nektar Therapeutics
Phase 1/2Completed557Apr 28, 2022Registry ↗
Mar 10, 2023Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic…
NCT03138889 · Non-Small Cell Lung Cancer
NKTR-214, Pembrolizumab
NKTR
Nektar Therapeutics
Phase 1/2Terminated162Jul 5, 2022Registry ↗
Mar 8, 2023REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanc…
NCT03435640 · Melanoma, Merkel Cell Carcinoma
NKTR-262, bempegaldesleukin
NKTR
Nektar Therapeutics
Phase 1/2Terminated64May 9, 2022Registry ↗
Jan 12, 2023BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PR…
NCT04969861 · Metastatic Head and Neck Cancer, Recurrent Head and Neck Ca…
Bempegaldesleukin, Pembrolizumab
NKTR
Nektar Therapeutics
Phase 2/3Terminated1Apr 22, 2022Registry ↗
Aug 2, 2021A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chron…
NCT01619839 · Osteoarthritis of the Knee
NKTR-181, Placebo
NKTR
Nektar Therapeutics
Phase 2Completed296Aug 2013Registry ↗
Jul 29, 2021A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Ad…
NCT02869295 · Unspecified Adult Solid Tumor, Protocol Specific
NKTR-214
NKTR
Nektar Therapeutics
Phase 1/2Completed28Oct 31, 2018Registry ↗
Jul 12, 2021An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
NCT01457118 · Malignant Solid Tumor
NKTR-102 145 mg/m2, NKTR-102 120 mg/m2
NKTR
Nektar Therapeutics
Phase 2Completed27Aug 2017Registry ↗
Jul 12, 2021NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal…
NCT00856375 · Colorectal Cancer
NKTR-102, irinotecan
NKTR
Nektar Therapeutics
Phase 2Completed83Jul 2014Registry ↗
Jul 12, 2021Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanc…
NCT00806156 · Tumor, Ovarian Cancer
NKTR-102 q14d, NKTR-102 q21d
NKTR
Nektar Therapeutics
Phase 2Completed178Oct 2012Registry ↗
Jul 12, 2021NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Meta…
NCT00598975 · Tumor, Colorectal Cancer
NKTR-102 100 mg/m2, NKTR-102 125 mg/m2
NKTR
Nektar Therapeutics
Phase 2Completed18May 2009Registry ↗
Jul 8, 2021A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C i…
NCT04955262 · Metastatic Melanoma
Bempegaldesleukin (NKTR-214), Nivolumab
NKTR
Nektar Therapeutics
Phase 1Withdrawn0Jun 2021Registry ↗
Jul 8, 2021A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-phy…
NCT03802227 · Moderate to Severe Chronic Pain
NKTR-181, Oxycodone IR
NKTR
Nektar Therapeutics
Phase 1Terminated8Dec 17, 2019Registry ↗
Jun 22, 2021Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chron…
NCT02367820 · Low Back Pain, Chronic Pain
NKTR-181 BID tablets
NKTR
Nektar Therapeutics
Phase 3Completed638Dec 2017Registry ↗
Jun 1, 2021The BEACON Study (Breast Cancer Outcomes With NKTR-102)
NCT01492101 · Locally Recurrent Breast Cancer, Metastatic Breast Cancer
NKTR-102, Treatment of Physician's Choice (TPC)
NKTR
Nektar Therapeutics
Phase 3Completed852Apr 2016Registry ↗
Sep 16, 2020Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain
NCT02362672 · Low Back Pain, Chronic Pain
NKTR-181 BID tablets, Placebo to match NKTR-181 BID tablets
NKTR
Nektar Therapeutics
Phase 3Completed1,189Dec 2016Registry ↗
Jul 9, 2018Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanc…
NCT00802945 · Tumor, Breast Cancer
NKTR-102, NKTR-102
NKTR
Nektar Therapeutics
Phase 2Completed70Oct 2011Registry ↗
Oct 6, 2017A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of N…
NCT01991678 · Advanced or Metastatic Solid Tumors in Patients With Hepati…
145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102
NKTR
Nektar Therapeutics
Phase 1Completed25May 2017Registry ↗
Dec 22, 2016A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol)…
NCT01976143 · Advanced Cancer, Metastatic Solid Tumors
NKTR-102
NKTR
Nektar Therapeutics
Phase 1Completed33Jun 2016Registry ↗

39 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:56 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances